跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 87,077 条关于
“NTRK1/2/3”
全部
87,077
临床试验
55,792
药物
9,748
机构
2,436
资讯
19,101
10个月前
Geneseeq's PanTRKare™ Receives NMPA Approval as China's First NGS-Based Pan-Solid Tumor Companion Diagnostic for NTRK Gene Fusions
去年
Tempus Study Shows Concurrent RNA and DNA Sequencing Improves Actionable Variant Detection in NSCLC
去年
Biomarker Testing Crucial for Personalized Treatment in Metastatic NSCLC, Experts Emphasize
去年
Avistone's ANS03, a Novel ROS1/NTRK Inhibitor, Receives FDA IND Clearance
去年
Repotrectinib Recommended for EU Approval in ROS1+ NSCLC and NTRK+ Solid Tumors
去年
EMA Committee Recommends Repotrectinib for ROS1-Positive NSCLC and NTRK-Positive Solid Tumors
去年
Lyra Therapeutics Completes Enrollment in Phase 3 Trial of LYR-210 for Chronic Rhinosinusitis
9个月前
Novo Nordisk's Amycretin Shows Promising Phase 2 Results in Type 2 Diabetes, Advances to Phase 3 Trials
去年
Bayer Advances Asundexian to Phase 3 Despite Phase 2 Efficacy Misses
11个月前
United Therapeutics Reports Phase 3 TETON-2 Trial Results in Conference Call
第 1 页,共 1911 页
上一页
下一页